Gene therapy for malignant pleural mesothelioma: present and future.
Malignant pleural mesothelioma is relatively rare in frequency but one of the intractable diseases linked with asbestos exposure. Clinical outcomes with the present treatment modalities are unsatisfactory and no effective prevention method has been reported. Growing numbers of the patients in the Western countries with a long latent period need development of a novel therapeutic strategy. Gene therapy is a candidate for mesothelioma treatment because of its easy accessibility of a vector-mediated gene medicine into the intrapleural cavity. Several preclinical studies demonstrated that the gene medicine produced antitumor effects, suggesting the feasibility in clinical settings. In this article, we review the current status of gene therapy and clinical trials targeting mesothelioma and address possible directions to improve the efficacy.
Tada
Yuji
Y
Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Takiguchi
Yuichi
Y
Hiroshima
Kenzo
K
Shimada
Hideaki
H
Ueyama
Taro
T
Nakamura
Makoto
M
Tatsumi
Koichiro
K
Kuriyama
Takayuki
T
Tagawa
Masatoshi
M
D002986:Clinical Trials as Topic; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008654:Mesothelioma / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D010997:Pleural Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D013937:Thymidine Kinase / Q000235:genetics / Q000378:metabolism
D016207:Cytokines; D013937:Thymidine Kinase